Roivant Leads Peers While Short Interest Climbs to a Year High

ROIV gained 5.3% over the past week, putting it at the top of a peer group that fell 0.7% at the median. Closest comparable IMVT added 4.7%, but CYTK dropped 14.8% and MLYS slid 15.7%, illustrating how sharply outcomes diverged across mid-cap biotech in the same period. Roivant's 9.4% gain over the past month and a close of $38.88 on November 6 compound that outperformance.

Short interest has quietly climbed to its highest level in at least a year, even as the stock has risen. ROIV's short interest reached 5.7% of the free float on November 5, up roughly 10% over the past month after a step-change higher in early October when shorts rose from around 36 million to roughly 39.5 million shares. The lending market, however, imposes no friction on that positioning: availability is running at 1,692%, meaning there are roughly seventeen shares available to borrow for every one already lent out. Borrowing costs are low at 0.42%, down 15% over the past month. The build in short interest is therefore a matter of conviction, not desperation.

Options positioning cuts in the opposite direction. The put/call ratio has fallen to 0.48, nearly 1.75 standard deviations below its 20-day average of 0.72, and the shift was abrupt: the PCR hovered above 0.78 through late October before dropping sharply at the start of November. That swing toward calls, the lowest relative put demand in a year outside of the February low of 0.22, suggests the options market is leaning bullish into the November 9 print.

The insider picture complicates that read. Eric Venker, Roivant's President and Immunovant CEO, sold $21.1 million in stock across three transactions in October and early November, all executed under a pre-arranged 10b5-1 plan. Planned sales carry less informational weight than discretionary ones, but the scale is notable: 90-day net insider selling across the company totals roughly $43.9 million. On the institutional side, BlackRock added 11 million shares in the quarter to September, filing a fresh 13G at 8.2% of shares. FMR LLC filed on November 5 disclosing an increase to 11.8% from 10.3%. Neither holds an activist 13D stake, and no activist is on the register.

The debate heading into the print centres on pipeline credibility. The bull case rests on mosliciguat's Phase II data in pulmonary arterial hypertension, where placebo-adjusted pulmonary vascular resistance fell 56.3% at week 16, and on brepocitinib's dermatomyositis approval adding a commercial anchor alongside VTAMA. Citigroup raised its target to $56 on October 28, keeping a Buy, and the analyst consensus sits at a mean target of $50 against a current price of $38.88. Bears point to a string of clinical failures including non-infectious uveitis and cutaneous sarcoidosis, unaudited financials adding transparency risk, and a pipeline where the remaining catalysts still carry binary outcomes. Wolfe Research stepped to the sidelines in mid-October, downgrading to Peer Perform.

The print will test whether the commercial and clinical progress the market has been rewarding, a 70% gain this year by some measures, is translating into a financial trajectory that justifies the growing short base's scepticism and the options market's new optimism at the same time.